Drug Profile
SB 300 family - Symic Bio
Alternative Names: SB-300Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator SYMIC Biomedical
- Developer Symic Bio
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis; Pulmonary fibrosis; Renal fibrosis
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Fibrosis in USA
- 28 Sep 2020 No recent reports of development identified for research development in Pulmonary-fibrosis in USA
- 28 Sep 2020 No recent reports of development identified for research development in Renal-fibrosis in USA